Table 2 Spectrum of high TMB (TMB-H) and high MSI (MSI-H) in the cohort.
Patient ID | Age | Gender | Cancer | Mutation no | Mutations | MSI% | TMB(mut/Mb) |
|---|---|---|---|---|---|---|---|
P1 | 67 | Female | FGT | 3 | ARID1A, PTEN | 35.3 | 19.8 |
P2 | 66 | Female | FGT | 10 | ARID1A, CDKN2A, KRAS, PIK3CA, PTEN, NBN, TSC2 and TP53 | 52.9 | 26.9 |
P3 | 43 | Female | FGT | 4 | ARID1A, KDM6A, PIK3CA, PTEN and TP53 | 42.0 | 44.4 |
P4 | 56 | Male | GIT | 4 | APC, MLH1, MRE11 | 37.2 | 62.9 |
P5 | 78 | Female | GIT | 5 | CDKN2A, MRE11, MLH1 and TP53 | 36.0 | 30.2 |
P6 | 75 | Male | GU | 4 | AR, MET and PTCH1 | 57.6 | 49.6 |
P7 | 10 | Male | CNS | 7 | ATM, ATRX, IDH2, MSH6, POLE, PTEN and RAD50 | 25.6 | 416.7 |
